NCT05832892 2024-06-14
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
Shanghai Zhongshan Hospital
Phase 1/2 Unknown
Clinical Trials
9 trialsNCT04902261 2023-09-01
Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer
Changhai Hospital
Phase 2 Unknown
NCT05634564 2022-12-05
Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT05327582 2022-04-14
An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT04808687 2021-03-22
Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03703063 2021-01-27
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
Benaroya Research Institute
Phase 1 Unknown
NCT04498689 2020-08-04
Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer
Fudan University
Phase 2 Unknown
NCT03668418 2018-09-12
xenoZ
University of Pisa
Unknown
NCT03636308 2018-08-17
ASAGPAC
Peking University
Phase 2 Unknown